Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.

J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022.

2.

[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].

Li B, Zhang GS, Dai CW, Pei MF.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):448-52. Chinese.

PMID:
15854548
3.

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.

Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.

J Allergy Clin Immunol. 2010 Oct;126(4):828-835.e3. doi: 10.1016/j.jaci.2010.06.049.

4.

[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].

Borbényi Z.

Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6. Review. Hungarian.

PMID:
15921304
5.

Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, Martínez J, López J, Suárez JG, Moreno MJ, Merino MA, Gutiérrez NC, Hernández-Rivas JM.

Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.

PMID:
22806436
6.

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.

Helbig G, Hus M, Hałasz M, Dudziński M, Więcławek A, Stachowicz M, Soja A, Kyrcz-Krzemień S.

Med Oncol. 2012 Jun;29(2):1073-6. doi: 10.1007/s12032-011-9831-1. Epub 2011 Jan 22.

PMID:
21258876
7.

Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.

Václavík J, Szotkowski T, Hutyra M, Kozák J, Lukl J, Táborský M.

Am J Hematol. 2010 Apr;85(4):296-9. doi: 10.1002/ajh.21635. No abstract available.

8.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G.

Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1.

9.

Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.

Dahabreh IJ, Giannouli S, Zoi C, Zoi K, Voulgarelis M, Moutsopoulos HM.

Medicine (Baltimore). 2007 Nov;86(6):344-54.

10.

Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.

Schwartz LB, Sheikh J, Singh A.

Curr Med Res Opin. 2010 Aug;26(8):1933-46. doi: 10.1185/03007995.2010.493132. Review.

PMID:
20565230
11.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6. Epub 2003 Jul 3.

12.

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.

Butterfield JH.

Leuk Res. 2009 Aug;33(8):1127-9. doi: 10.1016/j.leukres.2008.12.001. Epub 2009 Jan 13.

PMID:
19144405
13.

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.

Florian S, Esterbauer H, Binder T, Müllauer L, Haas OA, Sperr WR, Sillaber C, Valent P.

Leuk Res. 2006 Sep;30(9):1201-5. Epub 2006 Jan 6.

PMID:
16406018
14.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

15.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26.

PMID:
18307562
17.

[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].

Menif S, Ben Romdhane N, Hafsia R.

Rev Med Interne. 2008 Jan;29(1):65-7. Epub 2007 Oct 25. French.

PMID:
18036706
18.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

19.

Novel approaches to therapy of hypereosinophilic syndromes.

Simon HU, Cools J.

Immunol Allergy Clin North Am. 2007 Aug;27(3):519-27. Review.

PMID:
17868862
20.

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.

Vigna E, Lucia E, Gentile M, Mazzone C, Bisconte MG, Gentile C, Armentano A, Ottaviani E, Rondoni M, Martinelli G, Morabito F.

Cancer Chemother Pharmacol. 2008 Apr;61(4):713-6. Epub 2007 Jun 5.

PMID:
17549478

Supplemental Content

Support Center